Requests that the FDA grant permission to file an application for an abbreviated new animal drug application for a generic compressed chewable tablet for Trilostane that differs from the pioneer product, VETORYL CAPSULES, sponsored by Dechra Veterinary Products. under NADA 141-291. | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-P-7889

Requests that the FDA grant permission to file an application for an abbreviated new animal drug application for a generic compressed chewable tablet for Trilostane that differs from the pioneer product, VETORYL CAPSULES, sponsored by Dechra Veterinary Products. under NADA 141-291.

Documents

Comments

Key Dates

Comment Period OpensJul 16, 2026

Documents

Type	Title	Posted	Comments	Status
Supporting Material	Attachment 2	Jul 16, 2026	--

Keywords

CVM

Suitability Petition

Felix Pharmaceuticals Pvt Ltd

grant permission to file an application

for an abbreviated new animal drug application

for a generic

compressed chewable tablet for Trilostane

that differs from the pioneer product

Data from Regulations.gov